Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials.

Mol Clin Oncol · 2019 · PMC6388502 · PMID 30847174

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a possible trendno p-value reported

However, for the other subtypes, the rates were 43 and 60%, respectively (odds ratio = 0.50, P=0.25), indicating a possible trend toward worse outcome when Bev was added ( 33 ).

also in 1,410 other papers

a positive trendno p-value reported

However, the overall effect of Bev on OS exhibited a positive trend favoring Bev compared with non-Bev.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.